Beleave Inc.

BLEVF

CA0775611084

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 01:21:53 2024-04-04 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2020	Beleave Inc. Appoints Bill Panagiotakapoulos as Chief Restructuring Officer	CI
2020	Hegedus Consulting Services Inc. agreed to acquire Substantially All of the Assets from Beleave Inc. (CNSX:BE).	CI

Beleave Inc. Approves for Sales in the Province of Alberta

March 02, 2020 at 05:18 pm EST

Beleave Inc. announced that it is now approved for sales in the province of Alberta. The province, with over 400 licensed stores, has more retail locations than all other provinces combined and reported CAD 255 million in legal cannabis retail store sales in 2019 (as reported by StatsCan).

Latest news about Beleave Inc.

Beleave Inc. Appoints Bill Panagiotakapoulos as Chief Restructuring Officer	20-06-16	CI
Hegedus Consulting Services Inc. agreed to acquire Substantially All of the Assets from Beleave Inc. (CNSX:BE).	20-06-04	CI
Beleave Inc. Announces Management Changes	20-04-13	CI
Beleave Inc. announced that it expects to receive CAD 0.5 million in funding	20-03-02	CI
Beleave Inc. Enters LoI with Dutchman's Gold to Partner on Cannabis Infused Honey Products	20-03-02	CI
Beleave Inc. Approves for Sales in the Province of Alberta	20-03-02	CI
Beleave Expands Cannabis 2.0 Product Roll Out to British Columbia with Flyte Classic Vaporizer	20-02-26	CI
Beleave Inc. announced that it has received CAD 0.27 million in funding	20-02-25	CI
Beleave Inc. Announces New Product Line; Receives the Largest Purchase Order from A Province in the Company's History	19-12-19	CI
Beleave Inc. Announces Management Changes	19-12-19	CI
Beleave Announces Joint Venture with Volero Brands to Launch Cannabis 2.0 Products in Canada	19-10-31	CI
Beleave Inc. Announces Management Appointments	19-10-28	CI
Beleave Inc. (CNSX:BE) cancelled its acquisition of TerraFarma, Inc.	19-09-18	CI
Beleave Inc. (CNSX:BE) entered into a non-binding letter of intent to acquire TerraFarma, Inc.	19-08-06	CI
Beleave Inc. Announces Restated Interim Consolidated Financial Statements for the Nine Months Ended December 31, 2018	19-06-28	CI
Beleave Receives Green Light for Building Permit as Hamilton Phase 2 Expansion Moves Forward	19-06-24	CI
Beleave Inc. Moves Expansion of Its Hamilton Facility After Receiving Approval from the Hamilton City Council	19-05-23	CI
Beleave Inc. Receives Building Permit in the Health Canada Licensing Process for its Facility in London, Ontario	19-04-05	CI
Beleave Inc. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2018	19-03-04	CI
Beleave Appoints Amy Nederlander as a New Independent Director and an Independent Chairman of its Board	19-03-01	CI
Beleave Announces Management Changes	19-02-19	CI
Beleave Inc. Appoints Bill Panagiotakopoulos to the Board of Directors to Act as the Executive Chairman	19-01-16	CI
Beleave Inc. Provides Update and Clarification on GMP Certification Process	18-12-17	CI
Beleave Inc. Receives its Good Manufacturing Practices Certification	18-12-13	CI
Beleave Inc. Reports Consolidated Earnings Results for the Second Quarter Ended September 30, 2018; Provides Revenue Guidance for the Third Quarter of 2018	18-11-29	CI

Chart Beleave Inc.

Duration

Period

More charts

Company Profile

Beleave Inc. is a Canada-based cannabis company. Through its wholly owned subsidiary, Beleave Kannabis Corp, the Company is a license holder and producer of cannabis, which includes cultivation, processing, medical sales and research. Its segment includes Cannabis Products and Patient Network. Its Cannabis Products segment is a licensed producer of marihuana for medical purposes. Its Patient Network segment is a patient network of medical cannabis services. It cultivates cannabis flower, oil and extracts for medical and recreational markets. Its product line includes cannabis-infused products, oils and vape pens. The Company operates a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner.

Sector

Pharmaceuticals

More about the company

Sector Alternative Medicine

	1st Jan change	Capi.
BELEAVE INC.	0.00%	553
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.40%	1.38B

Alternative Medicine

Beleave Inc.

Equities

BLEVF

CA0775611084

Pharmaceuticals

Beleave Inc. Approves for Sales in the Province of Alberta

Latest news about Beleave Inc.

Chart Beleave Inc.

Company Profile

Sector Alternative Medicine